Covera Health and Medmo have merged into a single organization and will launch a platform that manages diagnostic imaging for nearly six million Americans across major employers and health plans.
Covera's AI-driven platform measures diagnostic accuracy at more than 1,100 imaging sites and routes members to higher-performing facilities, while Medmo's platform handles scheduling coordination, prior authorization, and results delivery, according to the companies. Together, the combined platform is designed to manage the full imaging journey from referral through results, the two firms said.
Covera’s Ron Vianu will continue as CEO of the combined organization, while Medmo CEO Lucas Takahashi will take on the role of president.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
